Alaw Therapeutics Advances Brain Penetrant CDK Inhibitor Programs

Alaw Therapeutics announced in a press release two key milestones for its cyclin dependent kinase inhibitor portfolio. The company has started dosing patients in a Phase 1a/b clinical trial for AL-605, a selective brain penetrant CDK2 inhibitor, and has nominated AL-433, a selective brain penetrant CDK4 inhibitor, as a new development candidate.

The AL-605 study is enrolling patients with CCNE1 amplified solid tumors, including hormone receptor positive breast cancer that has progressed after CDK4/6 inhibitor therapy. The trial will evaluate safety, pharmacokinetics, pharmacodynamics, and early antitumor activity, with interim data expected in the second half of 2026.

AL-433, designed for high selectivity toward CDK4 over CDK6, aims to improve tolerability and achieve effective central nervous system exposure. Preclinical studies showed that AL-433 achieves near complete blood brain barrier penetration and antitumor activity in CDK4 dependent brain tumor models. First in human clinical studies are planned for the fourth quarter of 2026.

Both programs are part of Alaw Therapeutics’ precision oncology pipeline focused on therapies that address resistance mechanisms and central nervous system limitations in targeted cancer treatment.